Global Drug-Eluting Stents Market

Report Highlights

The global market for drug-eluting stents should grow from $6.7 billion in 2019 to $9.3 billion by 2024 at a compound annual growth rate (CAGR) of 6.8% during the period of 2019-2024.

Report Includes

• 20 data tables and 18 additional tables
• An overview of global market for drug-eluting stents within the medical devices industry
• Estimation of the market size and analyses of market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
• Market share analysis of the drug-eluting stents based on product, application, end-use, and region
• Identification of segments with high growth potential and analysis of future applications of each of the segments
• Assessment of market dynamics for drug-eluting stents with market drivers and restraints explained, medical device regulations, market background and pipeline analysis of the stents
• Coverage of prevalence and epidemiology of cardiovascular disease and description of coronary artery disease (CAD) and peripheral artery disease (PAD)
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
• Company profiles of the leading market players, including Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corp., Medtronic Plc and Cook Medical Inc.

Report Scope

This report examines the current and projected market potential of drug-eluting stents. It offers a detailed analysis of the regulatory scenario, competitive environment, pipeline, technological advancement, drivers, restraints and market growth trends. The report also includes market projections through 2024 and the market rank for key market players. The report details the market share of drug-eluting stents based on types of product, application and end user.

By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents. By application, the market is segmented into coronary artery disease (CAD) and peripheral artery disease (PAD). By end user, the market is segmented into hospitals, ambulatory surgical centers and specialty centers and clinics.

By geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data is provided for 2018 as the base year, 2019 and forecast through year-end 2024. Estimated values used are based on drug-eluting stent manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

• Siemens: 360° Company Analysis (IFT322A)
• Thermo Fisher Scientific Inc.: 360° Company Analysis (HLC309A)
• Needle-Free Devices: Technologies and Global Markets (HLC178C)
• Koninklijke Philips N.V.: 360° Company Analysis (HLC308A)
• Global High Purity Quartz Market (CHM191A)